Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Block Listing Application

18 Mar 2016 15:34

RNS Number : 6335S
GW Pharmaceuticals PLC
18 March 2016
 

 

GW Pharmaceuticals PLC ("GW Pharmaceuticals")

 

BLOCK LISTING APPLICATION

 

Cambridge, UK, 18 March 2016: GW Pharmaceuticals (AIM: GWP, Nasdaq: GWPH) hereby provides notification that application has today been made to the London Stock Exchange for admission to trading on AIM of a block of 1,000,000 new ordinary shares of 0.1p each.

These new ordinary shares will be issued from time to time pursuant to the exercise of employee share options under the GW Pharmaceuticals Long Term Incentive Plan 2008.

On exercise the shares will be issued credited as fully paid and will rank pari passu with the existing ordinary shares in issue.

It is expected that such admission will become effective on 24 March 2016.

 

 

For further information, please contact:

 

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

 

Peel Hunt LLP (Nominated Adviser)

James Steel/Oliver Jackson +44 (0) 20 7418 8900

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
LISSFEFIAFMSEDD
Date   Source Headline
22nd Jun 20162:22 pmRNSHolding(s) in Company
21st Jun 201612:00 pmRNSEpidiolex Development Program in Infantile Spasms
17th Jun 20165:05 pmRNSHolding(s) in Company
8th Jun 20164:54 pmRNSHolding(s) in Company
31st May 20161:25 pmRNSTotal Voting Rights
31st May 201612:00 pmRNSPresents at Goldman Sachs and Jefferies Conference
16th May 201612:00 pmRNSGWP presenting at UBS Global Healthcare Conference
13th May 20163:50 pmRNSDirector/PDMR Shareholding
11th May 20165:19 pmRNSDirector/PDMR Shareholding
5th May 201612:00 pmRNSHalf-year Report
4th May 201612:00 pmRNSPresenting at BoAML 2016 Healthcare Conference
29th Apr 20161:37 pmRNSTotal Voting Rights
28th Apr 201612:00 pmRNSNotice of Results
21st Apr 201612:00 pmRNSOrphan Drug Designation for Cannabidiol in TSC
11th Apr 201612:00 pmRNSInitiates Ph 3 Study in Tuberous Sclerosis Complex
1st Apr 20163:24 pmRNSDirector/PDMR Shareholding
23rd Mar 20165:07 pmRNSResult of AGM
18th Mar 20163:34 pmRNSBlock Listing Application
14th Mar 201611:00 amRNSEpidiolex Positive Phase 3 Pivotal Study Results
29th Feb 20169:26 amRNSTotal Voting Rights
22nd Feb 20166:16 pmRNSNotice of AGM
17th Feb 201610:37 amRNSBlocklisting Interim Review
15th Feb 20162:39 pmRNSDirector/PDMR Shareholding
10th Feb 201612:00 pmRNS1st Quarter Results
4th Feb 20163:45 pmRNSPresenting at Leerink Global Healthcare Conference
2nd Feb 20163:07 pmRNSNotice of Results
29th Jan 201611:42 amRNSTotal Issued Share Capital
29th Jan 20169:29 amRNSHolding(s) in Company
28th Jan 20168:47 amRNSHolding(s) in Company
25th Jan 20168:33 amRNSHolding(s) in Company
6th Jan 201612:01 pmRNSPublication of UK Annual Report and Accounts
31st Dec 201510:42 amRNSTOTAL ISSUED SHARE CAPITAL
29th Dec 20152:26 pmRNSDirector/PDMR Shareholding
24th Dec 201512:00 pmRNSLancet Neurology Publishes Epidiolex Data
22nd Dec 20155:14 pmRNSDirector/PDMR Shareholding
21st Dec 20156:22 pmRNSDirector/PDMR Shareholding
16th Dec 20154:16 pmRNSDirector/PDMR Shareholding
16th Dec 20159:27 amRNSDirector/PDMR Shareholding
8th Dec 20157:00 amRNSFinal Results
7th Dec 20156:00 pmRNSNew Physician Reports of Epidiolex Treatment
30th Nov 20151:00 pmRNSDate and Time Change for Q4 and FY 2015 Results
30th Nov 20159:38 amRNSTotal Voting Rights
25th Nov 20152:00 pmRNSEpidiolex data to be presented at AES Meeting
24th Nov 20156:00 pmRNSNotice of Results
24th Nov 20156:00 pmRNSPresenting at Piper Jaffray Healthcare Conference
2nd Nov 201510:09 amRNSTotal Voting Rights
27th Oct 201511:05 amRNSAgreement with NSW to Study Epidiolex and CBDV
27th Oct 201511:00 amRNSResults from Sativex Phase 3 Cancer Pain Trials
15th Sep 20152:00 pmRNSPositive Proof of Concept Data in Schizophrenia
10th Sep 20152:00 pmRNSPresenting at Two Upcoming Investor Conferences

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.